Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Adenovirus
Research from University of Pittsburgh, Pittsburgh Cancer Institute reveals new findings on adenovirus
May 14th, 2008
New investigation results, 'Adenovirus MART-1-engineered autologous dendritic cell vaccine for metastatic melanoma,' are detailed in a study published in Journal of Immunotherapy. According to a study from the United States, "We performed a phase 1/2 trial testing the safety, toxicity, and immune response of a vaccine consisting of autologous dendritic cells (DCs) transduced with a replication-defective adenovirus (AdV) encoding the full-length melanoma antigen MART-1/Melan-A (MART-1). This vaccine was designed to activate MART-1-specific CD+8 and CD4+ T cells." "Metastatic melanoma patients received 3 injections of 106 or 10(7) DCs, delivered...
Source: Vaccine Weekly (2008-05-14)
|
